These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30397837)

  • 61. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
    Kaul S
    Diabetes Care; 2017 Jul; 40(7):821-831. PubMed ID: 28637887
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Updates on cardiovascular outcome trials in diabetes.
    Schnell O; Rydén L; Standl E; Ceriello A;
    Cardiovasc Diabetol; 2017 Oct; 16(1):128. PubMed ID: 29020969
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.
    Kaplan A; Abidi E; El-Yazbi A; Eid A; Booz GW; Zouein FA
    Heart Fail Rev; 2018 May; 23(3):419-437. PubMed ID: 29322280
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease.
    Mosleh W; Sharma A; Sidhu MS; Page B; Sharma UC; Farkouh ME
    Cardiovasc Drugs Ther; 2017 Jun; 31(3):311-318. PubMed ID: 28536852
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
    Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
    Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2018 Jun; 17(1):85. PubMed ID: 29895290
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
    Neal B; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Stein P; Desai M; Shaw W; Jiang J; Vercruysse F; Meininger G; Matthews D
    Am Heart J; 2013 Aug; 166(2):217-223.e11. PubMed ID: 23895803
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?
    Vargas Delgado AP; Requena Ibañez JA; Santos-Gallego CG; Badimon JJ
    Clin Investig Arterioscler; 2020 Oct; ():. PubMed ID: 34756346
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Macrovascular Risk Equations Based on the CANVAS Program.
    Willis M; Asseburg C; Slee A; Nilsson A; Neslusan C
    Pharmacoeconomics; 2021 Apr; 39(4):447-461. PubMed ID: 33580867
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Surprises in cardiology: efficacy of gliflozines in heart failure even in the absence of diabetes.
    Bragagni A; Piani F; Borghi C
    Eur Heart J Suppl; 2021 Oct; 23(Suppl E):E40-E44. PubMed ID: 34650352
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.
    Yi TW; Wong MMY; Neuen BL; Arnott C; Poirier P; Seufert J; Slee A; Rapattoni W; Ang FG; Wheeler DC; Mahaffey KW; Perkovic V; Levin A
    Diabetes Obes Metab; 2023 Jul; 25(7):2043-2047. PubMed ID: 36974373
    [No Abstract]   [Full Text] [Related]  

  • 72. Sodium-glucose co-transporter-2 inhibitors: A cardiovascular outcome trial analysis.
    Suvarna VR
    Perspect Clin Res; 2021; 12(1):4-8. PubMed ID: 33816202
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Maternal Mortality: 20"×20" Acrylic on Stretched Canvas.
    Aziz T
    Obstet Gynecol; 2022 Jun; 139(6):1189-1190. PubMed ID: 35675618
    [No Abstract]   [Full Text] [Related]  

  • 74. CANVAS is an Oligosymptomatic Disease.
    Ruiz-Fernández E; Calatayud-Lallana LM; Fraile-Rodrigo J; Gazulla J
    Ann Indian Acad Neurol; 2022; 25(3):530-533. PubMed ID: 35936596
    [No Abstract]   [Full Text] [Related]  

  • 75. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME
    Kadowaki T; Nangaku M; Hantel S; Okamura T; von Eynatten M; Wanner C; Koitka-Weber A
    J Diabetes Investig; 2019 May; 10(3):760-770. PubMed ID: 30412655
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Kelly MS; Lewis J; Huntsberry AM; Dea L; Portillo I
    Postgrad Med; 2019 Jan; 131(1):31-42. PubMed ID: 30449220
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease.
    Inoue M; Hayashi A; Taguchi T; Arai R; Sasaki S; Takano K; Inoue Y; Shichiri M
    J Diabetes Investig; 2019 Jul; 10(4):1004-1011. PubMed ID: 30461221
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
    Ueda P; Svanström H; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Pasternak B
    BMJ; 2018 Nov; 363():k4365. PubMed ID: 30429124
    [TBL] [Abstract][Full Text] [Related]  

  • 80. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Furtado RHM; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Lancet; 2019 Jan; 393(10166):31-39. PubMed ID: 30424892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.